Diametric Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Diametric Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,042	Closed	-$622K	–	126
2020 Q2	$622K	Buy	5,042 +1,099	+28%	+$109K	0.48%	69
2020 Q1	$333K	Sell	3,943 -14,506	-79%	-$1.25M	0.4%	71
2019 Q4	$1.56M	Buy	+18,449	New	+$1.39M	1.14%	32
2018 Q4	–	Sell	-7,062	Closed	-$685K	–	104
2018 Q3	$685K	Buy	+7,062	New	+$705K	0.6%	60

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Diametric Capital's BMRN Position: Q3 2020 in Review

Diametric Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 5,042 shares — an estimated $622K sold.

Diametric Capital first reported a position in BMRN in Q3 2018 and held it in 4 quarters. The position peaked at $1.56M in Q4 2019. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Diametric Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Diametric Capital sold 5,042 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $622K.
Diametric Capital first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Diametric Capital's BioMarin Pharmaceuticals position peaked at $1.56M in Q4 2019.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.